NasdaqGS:MDGLBiotechs
Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors
The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 2027, even as phase 3 data showed weight loss of up to 22.6% and blood sugar benefits. This mix of regulatory delay and clinical progress can reshape expectations for companies exposed to these therapies. For investors, it creates a fresh reason to reassess risk, timing and potential rewards. The sections that follow break down how three...